US › Healthcare

Recursion Pharmaceuticals Inc (RXRX)

US · Healthcare · Biotechnology

$3.31+4.09%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$6.5M
Revenue YoY
-56.1%
Net profit
$-117.5M
Profit YoY
+42.0%
EPS
$-0.22
EPS estimate
$-0.26
Net margin
-1,815.6%

EPS came in at -0.22 against a street estimate of -0.26 — a beat of 15.4%.

Key statistics

Market cap
$1.69B
Forward P/E
0.0
P/B
1.55
Book value
$1.93
EPS (TTM)
$-1.16
52-week high
$7.18
52-week low
$2.77
50-day MA
$3.30
200-day MA
$3.91
Beta
1.05

Analyst view

Analysts rate Recursion Pharmaceuticals Inc a hold (2 buy, 6 hold, 0 sell out of 8) with an average price target of $7.25.

Shareholding

Insiders
2.37%
Institutions
68.90%

Largest institutional holders

FundStake
Vanguard Group Inc8.89%
BlackRock Inc8.14%
ARK Investment Management LLC7.58%
State Street Corp5.37%
Baillie Gifford & Co Limited.4.46%
Vanguard Portfolio Management, LLC4.29%
Vanguard Capital Management, LLC4.19%
SoftBank Group Corp2.57%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Recursion Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.